| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFB103B |
| Uniprot No | P81534 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-67aa |
| 氨基酸序列 | GIINTLQKYYCRVRGGRCAVLSCLPKEEQI GKCSTRGRKCCRRKK |
| 预测分子量 | 5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFB103B(β-防御素103B)重组蛋白的参考文献示例，信息基于公开研究内容整理：
---
1. **标题**：*Recombinant Human Beta-Defensin 3 (DEFB103B) Exhibits Broad-Spectrum Antimicrobial Activity*
**作者**：Harder J, et al.
**摘要**：研究报道了DEFB103B重组蛋白在体外对细菌、真菌和包膜病毒的抗微生物活性，并探讨其通过破坏微生物膜结构发挥作用的机制。
2. **标题**：*Expression and Purification of Functional DEFB103B in a Prokaryotic System*
**作者**：Chen X, et al.
**摘要**：成功在大肠杆菌中表达并纯化具有生物活性的DEFB103B重组蛋白，优化了包涵体复性条件，验证其对金黄色葡萄球菌的抑菌效果。
3. **标题**：*DEFB103B Modulates Immune Response in Chronic Inflammatory Skin Diseases*
**作者**：Niyonsaba F, et al.
**摘要**：发现DEFB103B重组蛋白通过激活角质形成细胞的TLR通路增强先天免疫反应，提示其在银屑病等炎症性皮肤病中的潜在治疗价值。
4. **标题**：*Structural Analysis of DEFB103B Reveals Key Residues for Chemotactic Function*
**作者**：Semple CA, et al.
**摘要**：通过重组蛋白的晶体结构解析，鉴定了DEFB103B中与免疫细胞趋化作用相关的关键氨基酸位点，为设计功能类似物提供依据。
---
注：以上文献标题和内容根据领域内典型研究方向模拟，实际引用时请核实具体论文信息。
DEFB103B, also known as human beta-defensin 103B, is a small cationic antimicrobial peptide belonging to the defensin family. These evolutionarily conserved proteins play critical roles in innate immunity, acting as the first line of defense against microbial pathogens. The DEFB103 gene is located on chromosome 20q11.1 within a cluster of beta-defensin genes, and DEFB103B represents a splice variant of the DEFB103 gene, differing in its N-terminal sequence compared to the canonical DEFB103A isoform.
As a cationic host defense peptide, DEFB103B exhibits broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses through membrane disruption and immunomodulatory functions. Its mechanism involves electrostatic interactions with negatively charged microbial membranes, leading to pore formation and pathogen lysis. Beyond direct microbicidal effects, DEFB103B interacts with immune cells to modulate chemokine production and recruit leukocytes, bridging innate and adaptive immunity.
Recombinant DEFB103B protein is typically produced using heterologous expression systems such as E. coli or mammalian cell cultures, enabling large-scale production for research and therapeutic development. The recombinant form retains the native protein's structural features, including six conserved cysteine residues forming three disulfide bonds critical for its stable β-sheet structure and functional integrity.
Current research focuses on its potential therapeutic applications, particularly in combating antibiotic-resistant infections and chronic inflammatory conditions. Studies explore its synergistic effects with conventional antibiotics, wound-healing properties, and role in mucosal immunity. Challenges remain in optimizing production yields, maintaining stability in physiological environments, and understanding tissue-specific expression regulation. As antimicrobial resistance escalates globally, DEFB103B represents a promising template for developing novel peptide-based therapeutics.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
